Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JW0106 + C2101
- Development stage
- Phase 1
- Lead developer
- JW Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JW0106 + C2101 is a combination drug regimen developed by JW Pharmaceutical for the management of dyslipidemia and hypertension. The regimen consists of the co-administration of two separate components: JW0106, which is a fixed-dose combination of the HMG-CoA reductase inhibitor pitavastatin and the angiotensin II receptor blocker (ARB) valsartan, and C2101, which is the calcium channel blocker (CCB) amlodipine. Pitavastatin reduces cholesterol levels by inhibiting hepatic cholesterol synthesis, while valsartan and amlodipine work through distinct mechanisms to lower blood pressure—valsartan by blocking the AT1 receptor to prevent vasoconstriction and amlodipine by inhibiting calcium influx into vascular smooth muscle to promote vasodilation. This combination is typically evaluated in clinical trials to compare its safety and pharmacokinetic profile against a single triple-combination tablet, JW0107.
- Other names
- pitavastatin + valsartan + amlodipine
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)AGTR1 (Angiotensin II Type-1 receptor)LTCC (Voltage-gated calcium channel (L-type))
Beyond the preview
Go deeper on JW0106 + C2101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JW0106 + C2101.